题名

Pharmacological Studies on Patients with Schizophrenia in Taiwan: A Compilation of Literature

并列篇名

台灣精神分裂症藥物治療：文獻整理

DOI

10.29478/TJP.201203.0001

作者

白雅美(Ya-Mei Bai)

关键词

抗精神病藥物 ； 精神分裂症 ； 台灣 ； Antipsychotic drugs ； schizophrenia ； Taiwan

期刊名称

台灣精神醫學

卷期/出版年月

26卷1期（2012 / 03 / 01）

页次

3+12 - 24

内容语文

英文
中文摘要

背景：台灣精神醫學界對精神分裂症之藥物學研究成果非常豐富，擬為近年來發表於國際期刊論文作分類摘要整理。方法：以「抗精神病藥物」、「精神分裂症」及「台灣」為關鍵字，於醫學期刊文獻資料庫（PubMed）搜尋台灣精神醫學界發表於國際期刊之論文。結果：研究論文依主題整理分為十類，包括療效研究、劑量調整、合併療法、藥物動力學、認知功能、治療預後、藥物副作用、藥物流行病學、藥物經濟學及藥物基因等類別。整體而言，除clozapine顯示有較佳療效外，其他抗精神病藥物療效相當，但副作用則有顯著差異。本土研究於藥物副作用之監測及處理、劑量調整、合併療法、藥物動力學等研究已有重要成果，可為臨床處理重要參考資料。療效及副作用的藥物基因學研究也相當豐富，為未來個人化治療提供重要資料，但仍需更多研究來驗證結果。相對而言在藥物認知功能、臨床預後及藥物經濟學的研究則較少。結論：台灣精神醫學界於精神分裂症之藥物學研究已有豐富研究成果，將可作為台灣精神分裂症藥物治療共識之基礎。
英文摘要

Our Taiwan psychiatrists have actively studied pharmacotherapy in patients with schizophrenia. A compilation of lileration on this topic to gain an overview of pharmacological studies of schizophrenia in Taiwan is useful for psychiatrists in Taiwan to get quick and handy references. I identified Science Citation Index (SCI)-papers with the electronic search on the key words ”antipsychotic,” ”schizophrenia,” and ”Taiwan” in PubMed (www.ncbi.nlm.nih.gov/pubmed). These articles were identified and annotated into 10 categories: (A) efficacy studies, including randomized double blind comparative studies, randomized single blind comparative studies, and open trials; (B) dose tuning; (C) augmentation therapy; (D) pharamcokinetic studies; (E) cognitive function; (F) prognosis; (G) side effects; (H) pharmaco-epidemiology; (I) pharmaco-economics; (J) pharmaco-genetics. Many Taiwan studies have offered empirical results of pharmacotherapy for schizophrenia in Taiwan. Besides clozapine, which is superior in efficacy, most studies showed comparable efficacy in treating schizophrenia among the different antipsychotic drugs, but with different side effect profiles. Many studies on monitoring and managing the side effects offered important references. The reports on dose tuning, augmentation with pharmacokinetic interaction, combination therapy or NMDA augmentation offered empirical evidence for clinical applications. The pharmaco-genetic studies showed evidence of genetic markers to predict efficacy and side effects in our Taiwan patients, trying to achieve the goal of individualized pharmacotherapy. But more studies are required to validate the results. The studies on cognition, clinical outcomes, pharmaco-economics are still limited in number. These studies have offered empirical results of pharmacotherapy for schizophrenia in Taiwan, and will be the basis for the development of the Taiwan consensus of pharmacological treatment for schizophrenia.
主题分类 醫藥衛生 > 社會醫學
参考文献
  1. Bai, Y. M.,Chen, J. Y.,Chen, T. T.(2009).Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients.Schizophr Res,108,122-6.
  2. Bai, Y. M.,Chen, J. Y.,Yang, W. S.(2007).Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia.J Clin Psychiatry,68,1834-9.
  3. Bai, Y. M.,Chen, T. T.,Lin, W. K.(2007).Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.J Clin Psychopharmacol,27,306-8.
  4. Bai, Y. M.,Chen, T. T.,Liou, Y. J.,Hong, C. J.,Tsai, S. J.(2011).Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.Schizophr Res,125,179-86.
  5. Bai, Y. M.,Chen, T. T.,Wu, B.(2006).A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study.Pharmacopsychiatry,39,135-41.
  6. Bai, Y. M.,Chen, T. T.,Yang, W. S.(2009).Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study.Schizophr Res,111,1-8.
  7. Bai, Y. M.,Lin, C. C.,Chen, J. Y.,Chen, T. T.,Su, T. P.,Chou, P.(2011).Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study.J Clin Psychiatry,72,751-6.
  8. Bai, Y. M.,Lin, C. C.,Chen, J. Y.,Lin, C. Y.(1999).Weight gain among patients on clozapine.Psychiatr Serv,50,704-5.
  9. Bai, Y. M.,Lin, C. C.,Chen, J. Y.,Lin, C. Y.,Su, T. P.,Chou, P.(2006).Association of initial antipsychotic response to clozapine and long-term weight gain.Am J Psychiatry,163,1276-9.
  10. Bai, Y. M.,Lin, C. C.,Chen, J. Y.,Liu, W. C.(2001).Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study.J Clin Psychopharmacol,21,608-11.
  11. Bai, Y. M.,Yu, S. C.,Chen, J. Y.,Lin, C. Y.,Chou, P.,Lin, C. C.(2005).Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study.Int Clin Psychopharmacol,20,79-85.
  12. Bai, Y. M.,Yu, S. C.,Lin, C. C.(2003).Risperidone for severe tardive dyskinesia: a 12-week randomized, doubleblind, placebo-controlled study.J Clin Psychiatry,64,1342-8.
  13. Chan, H. Y.,Chiang, S. C.,Chang, C. J.(2010).A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.J Clin Psychiatry,71,1226-33.
  14. Chan, H. Y.,Lin, W. W.,Lin, S. K.(2007).Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.J Clin Psychiatry,68,29-36.
  15. Chang, H. C.,Tang, C. H.,Tsai, S. J.,Yen, F. C.,Su, K. P.(2009).Longacting injectable risperidone and hospital readmission: a mirror-image study using a national claimbased database in Taiwan.J Clin Psychiatry,70,141.
  16. Chang, W. H.,Lin, S. K.,Lane, H. Y.,Hu, W. H.,Jann, M. W.,Lin, H. N.(1997).Clozapine dosages and plasma drug concentrations.J Formos Med Assoc,96,599-605.
  17. Chang, Y. C.,Lane, H. Y.,Yang, K. H.,Huang, C. L.(2006).Optimizing early prediction for antipsychotic response in schizophrenia.J Clin Psychopharmacol,26,554-9.
  18. Chen, C. H.,Chiu, C. C.,Huang, M. C.,Wu, T. H.,Liu, H. C.,Lu, M. L.(2008).Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.Prog Neuropsychopharmacol Biol Psychiatry,32,925-31.
  19. Chen, C. K.,Chen, Y. C.,Huang, Y. S.(2009).Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.Psychiatry Clin Neurosci,63,17-22.
  20. Chen, J. Y.,Bai, Y. M.,Pyng, L. Y.,Lin, C. C.(2001).Risperidone for tardive dyskinesia.Am J Psychiatry,158,1931-2.
  21. Chen, P. S.,Yang, Y. K.,Su. S. F.,Liao, Y. C.,Chang, J. W.,Yeh, T. L.(2004).Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.Psychiatry Clin Neurosci,58,168-72.
  22. Chen, S. F.,Shen, Y. C.,Chen, C. H.(2009).Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.Prog Neuropsychopharmacol Biol Psychiatry,33,470-4.
  23. Chen, S. F.,Shen, Y. C.,Chen, C. H.(2009).HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.Psychopharmacology (Berl),205,285-92.
  24. Chiu, C. C.,Chen, C. H.,Chen, B. Y.,Yu, S. H.,Lu, M. L.(2010).The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine.Prog Neuropsychopharmacol Biol Psychiatry,34,866-70.
  25. Chiu, C. C.,Chen, K. P.,Liu, H. C.,Lu, M. L.(2006).The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients.J Clin Psychopharmacol,26,504-7.
  26. Chiu, C. C.,Lane, H. Y.,Huang, M. C.(2004).Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia.J Clin Pharmacol,44,1385-90.
  27. Chiu, N. Y.,Yang, Y. K.,Chen, P. S.,Chang, C. C.,Lee, I. H.,Lee, J. R.(2003).Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial.Psychiatry Clin Neurosci,57,478-84.
  28. Chong, M. Y.,Tan, C. H.,Fujii, S.(2004).Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change.Psychiatry Clin Neurosci,58,61-7.
  29. Gau, S. S.,Chung, C. H.,Gau, C. S.(2008).A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.J Clin Psychopharmacol,28,271-8.
  30. Hong, C. J.,Chen, J. Y.,Chiu, H. J.,Sim, C. B.(1997).A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia.Int Clin Psychopharmacol,12,123-30.
  31. Hong, C. J.,Chen, T. T.,Bai, Y. M.,Liou, Y. J.,Tsai, S. J.(2012).Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.World J Biol Psychiatry,13,22-9.
  32. Hong, C. J.,Lin, C. H.,Yu, Y. W.,Yang, K. H.,Tsai, S. J.(2001).Genetic variants of the serotonin system and weight change during clozapine treatment.Pharmacogenetics,11,265-8.
  33. Hong, C. J.,Liou, Y. J.,Bai, Y. M.,Chen, T. T.,Wang, Y. C.,Tsai, S. J.(2010).Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.Pharmacogenet Genomics,20,359-66.
  34. Hong, C. J.,Yu, Y. W.,Lin, C. H.,Cheng, C. Y.,Tsai, S. J.(2001).Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia.Psychiatr Genet,11,219-22.
  35. Hong, C. J.,Yu, Y. W.,Lin, C. H.,Tsai, S. J.(2003).An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients.Neurosci Lett,349,206-8.
  36. Hsiao, C. C.,Ree, S. C.,Chiang, Y. L.,Yeh, S. S.,Chen, C. K.(2004).Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan.Psychiatry Clin Neurosci,58,403-9.
  37. Hsu, W. Y.,Huang, S. S.,Lee, B. S.,Chiu, N. Y.(2010).Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.J Clin Psychopharmacol,30,230-4.
  38. Huang, S. S.,Liao, Y. C.,Hsieh, Y. Y.(2006).Combination antipsychotic therapy in psychiatric outpatient clinics in Taiwan.Compr Psychiatry,47,421-5.
  39. Huang, T. L.,Chen, J. F.(2005).Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan.Schizophr Res,80,55-9.
  40. Hwang, T. J.,Lee, S. M.,Sun, H. J.(2003).Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.J Formos Med Assoc,102,30-6.
  41. Hwang, T. J.,Lin, S. K.,Lin, H. N.(2001).Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol.J Formos Med Assoc,100,811-6.
  42. Lai, I. C.,Chen, M. L.,Wang, Y. C.(2011).Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia.World J Biol Psychiatry,12,143-8.
  43. Lai, I. C.,Mo, G. H.,Chen, M. L.(2011).Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia.Eur J Clin Pharmacol,67,383-8.
  44. Lai, Y. C.,Huang, M. C.,Chen, C. H.,Tsai, C. J.,Pan ,C. H.,Chiu, C. C.(2009).Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone longacting injection in Chinese patients with schizophrenic and schizoaffective disorders.Psychiatry Clin Neurosci,63,440-8.
  45. Lane, H. Y.,Chang, Y. C.,Chiu, C. C.,Chen, M. L.,Hsieh, M. H.,Chang, W. H.(2002).Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.Am J Psychiatry,159,1593-5.
  46. Lane, H. Y.,Chang, Y. C.,Chiu, C. C.,Lee, S. H.,Lin, C. Y.,Chang, W. H.(2004).Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.Psychopharmacology (Berl),172,393-9.
  47. Lane, H. Y.,Chang, Y. C.,Liu, Y. C.,Chiu, C. C.,Tsai, G. E.(2005).Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, doubleblind, placebo-controlled study.Arch Gen Psychiatry,62,1196-204.
  48. Lane, H. Y.,Chiu, W. C.,Chou, J. C.,Wu, S. T.,Su, M. H.,Chang, W. H.(2000).Risperidone in acutely exacerbated schizophrenia dosing strategies and plasma levels.J Clin Psychiatry,61,209-14.
  49. Lane, H. Y.,Hsu, S. K.,Liu, Y. C.,Chang, Y. C.,Huang, C. H.,Chang, W. H.(2005).Dopamine D3 receptor Ser9Gly polymorphism and risperidone response.J Clin Psychopharmacol,25,6-11.
  50. Lane, H. Y.,Huang, C. L.,Wu, P. L.,Liu, Y. C.,Chang, Y. C.,Lin, P. Y.(2006).Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.Biol Psychiatry,60,645-9.
  51. Lane, H. Y.,Lee, C. C.,Chang, Y. C.,Lu, C. T.,Huang, C. H.,Chang, W. H.(2004).Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.Int J Neuropsychopharmacol,7,461-70.
  52. Lane, H. Y.,Lin, C. C.,Huang, C. H.,Chang, Y. C.,Hsu, S. K.,Chang, W. H.(2004).Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders.Schizophr Res,67,63-70.
  53. Lane, H. Y.,Lin, C. H.,Huang, Y. J.,Liao, C. H.,Chang, Y. C.,Tsai, G. E.(2010).A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.Int J Neuropsychopharmacol,13,451-60.
  54. Lane, H. Y.,Liu, Y. C.,Huang, C. L.(2008).RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia.J Clin Psychopharmacol,28,64-8.
  55. Lane, H. Y.,Liu, Y. C.,Huang, C. L.(2008).Sarcosine (Nmethylglycine) treatment for acute schizophrenia: a randomized, double-blind study.Biol Psychiatry,63,9-12.
  56. Lee, I. H.,Chen, P. S.,Yang, Y. K.(2008).The functionality and economic costs of outpatients with schizophrenia in Taiwan.Psychiatry Res,158,306-15.
  57. Lee, S. M.,Chou, Y. H.,Li, M. H.,Wan, F. J.,Yen, M. H.(2007).Effects of antipsychotics on cognitive performance in drugnaive schizophrenic patients.Prog Neuropsychopharmacol Biol Psychiatry,31,1101-7.
  58. Li, C. T.,Su, T. P.,Chou, Y. H.(2010).Symptomatic resolution among Chinese patients with schizophrenia and associated factors.J Formos Med Assoc,109,378-88.
  59. Liang, C. S.,Ho, P. S.,Shen, L. J.,Lee, W. K.,Yang, F. W.,Chiang, K. T.(2010).Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study.Schizophr Res,119,138-44.
  60. Lin, C. C.,Bai, Y. M.,Chen, J. Y.(2010).Easy and low-cost identification of metabolic syndrome in patients treated with second-generation antipsychotics: artificial neural network and logistic regression models.J Clin Psychiatry,71,225-34.
  61. Lin, C. C.,Bai, Y. M.,Wang, Y. C.(2009).Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics.J Clin Psychopharmacol,29,529-36.
  62. Lin, C. H.,Chou, L. S.,Hsu, C. Y.,Chen, Y. S.,Lane, H. Y.(2007).Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine.J Clin Psychiatry,68,1522-7.
  63. Lin, C. H.,Lin, S. C.,Chen, M. C.,Wang, S. Y.(2006).Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone.J Chin Med Assoc,69,264-9.
  64. Lin, H. C.,Chong, M. Y.,Lee, Y.,Yeh, W. C.,Lin, P. Y.(2009).Switching of antipsychotics to aripiprazole in the treatment of schizophrenia.Chang Gung Med J,32,409-16.
  65. Lin, S. K.,Su, S. F.,Pan, C. H.(2006).Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms.Ther Drug Monit,28,303-7.
  66. Liou, Y. J.,Bai, Y. M.,Lin, E.(2012).Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.Pharmacogenomics J,12,54-61.
  67. Liou, Y. J.,Chen, M. L.,Wang, Y. C.(2009).Analysis of genetic variations in the human Par-4 (PAWR) gene and tardive dyskinesia in schizophrenia.Am J Med Genet B Neuropsychiatr Genet,150B,439-40.
  68. Liou, Y. J.,Chen, M. L.,Wang, Y. C.(2009).Analysis of genetic variations in the RGS9 gene and antipsychoticinduced tardive dyskinesia in schizophrenia.Am J Med Genet B Neuropsychiatr Genet,150B,239-42.
  69. Liou, Y. J.,Lai, I. C.,Liao, D. L.(2006).The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia.Schizophr Res,86,323-5.
  70. Liou, Y. J.,Lai, I. C.,Lin, M. W.(2006).Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia.Pharmacogenet Genomics,16,151-7.
  71. Liou, Y. J.,Lai, I. C.,Wang, Y. C.(2006).Genetic analysis of the human ENTH (Epsin 4) gene and schizophrenia.Schizophr Res,84,236-43.
  72. Liou, Y. J.,Liao, D. L.,Chen, J. Y.(2004).Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients.Neuromolecular Med,5,243-51.
  73. Liou, Y. J.,Wang, Y. C.,Bai, Y. M.(2004).Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients.Neuropsychobiology,49,167-73.
  74. Liou, Y. J.,Wang, Y. C.,Chen, J. Y.(2008).The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia.Eur J Neurol,15,1406-8.
  75. Liou, Y. J.,Wang, Y. C.,Lin, C. C.(2005).Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan.Int J Neuropsychopharmacol,8,483-6.
  76. Liu, C. Y.,Chiu, N. Y.,Wu, C. K.,Yuan, L. M.,Hsiao, M. C.,Liao, O.(2003).Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.Int Clin Psychopharmacol,18,49-51.
  77. Liu, H. C.,Chang, W. H.,Wei, F. C.,Lin, S. K.,Jann, M. W.(1996).Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients.Ther Drug Monit,18,200-7.
  78. Liu, S. K.,Chen, W. J.,Chang, C. J.,Lin, H. N.(2000).Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol.Neuropsychopharmacology,22,311-9.
  79. Liu, Y. R.,Loh, E. W.,Lan, T. H.(2010).ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics.Pharmacogenomics J,10,30-9.
  80. Lu, M. L.,Lane, H. Y.,Chen, K. P.,Jann, M. W.,Su, M. H.,Chang, W. H.(2000).Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.J Clin Psychiatry,61,594-9.
  81. Lu, M. L.,Lane, H. Y.,Lin, S. K.,Chen, K. P.,Chang, W. H.(2004).Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.J Clin Psychiatry,65,766-71.
  82. Lu, M. L.,Shen, W. W.,Chen, C. H.(2008).Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.Prog Neuropsychopharmacol Biol Psychiatry,32,1978-81.
  83. Mo, G. H.,Lai, I. C.,Wang, Y. C.(2007).Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia.Schizophr Res,97,302-4.
  84. Shen, Y. C.,Chen, S. F.,Chen, C. H.(2009).Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.J Psychiatr Res,43,600-6.
  85. Sim, K.,Su, A.,Leong, J. Y.(2004).High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study.Pharmacopsychiatry,37,175-9.
  86. Sim, K.,Su, A.,Ungvari, G. S.(2004).Depot antipsychotic use in schizophrenia: an East Asian perspective.Hum Psychopharmacol,19,103-9.
  87. Sim, K.,Su, H. C.,Fujii, S.(2009).High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies.Br J Clin Pharmacol,67,110-7.
  88. Tsai, S. J.,Hong, C. J.,Yu, Y. W.(2000).Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response.Schizophr Res,44,177-81.
  89. Tsai, S. J.,Wang, Y. C.,Yu, Younger W. Y.,Lin, C. H.,Yang, K. H.,Hong, C. J.(2001).Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response.Schizophr Res,49,53-8.
  90. Wang, Y. C.,Bai, Y. M.,Chen, J. Y.,Lin, C. C.,Lai, I. C.,Liou, Y. J.(2010).Genetic association between TNF-alpha -308 G>A polymorphism and longitudinal weight change during clozapine treatment.Hum Psychopharmacol,25,303-9.
  91. Wang, Y. C.,Bai, Y. M.,Chen, J. Y.,Lin, C. C.,Lai, I. C.,Liou, Y. J.(2005).C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population.Pharmacogenet Genomics,15,743-8.
  92. Wang, Y. C.,Bai, Y. M.,Chen, J. Y.,Lin, C. C.,Lai, I. C.,Liou, Y. J.(2005).Polymorphism of the adrenergic receptor alpha 2a -1291C > G genetic variation and clozapine-induced weight gain.J Neural Transm,112,1463-8.
  93. Wang, Y. C.,Liou, Y. J.,Liao, D. L.(2004).Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients.J Neural Transm,111,623-9.
  94. Wu, M. K.,Wang, C. K.,Bai, Y. M.,Huang, C. Y.,Lee, S. D.(2007).Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program.Psychiatr Serv,58,544-50.
  95. Wu, T. H.,Chiu, C. C.,Shen, W. W.(2008).Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors.Prog Neuropsychopharmacol Biol Psychiatry,32,1889-93.
  96. Yang, S. Y.,Kao, Yang Y. H.,Chong, M. Y.,Yang, Y. H.,Chang, W. H.,Lai, C. S.(2007).Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study.Clin Pharmacol Ther,81,586-94.
  97. Yu, Y. W.,Tsai, S. J.,Lin, C. H.,Hsu, C. P.,Yang, K. H.,Hong, C. J.(1999).Serotonin-6 receptor variant (C267T) and clinical response to clozapine.Neuroreport,10,1231-3.
  98. Yu, Y. W.,Tsai, S. J.,Yang, K. H.,Lin, C. H.,Chen, M. C.,Hong, C. J.(2001).Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine.Neuropsychobiology,43,79-82.
被引用次数
  1. Shen, Winston W.,Rubio, Gabriel,Pérez-Nieto, Miguel A.,Noriega, Concha,Moreno, Raquel,Molina, Juan D.,López-Muñoz, Francisco,Cecilio Álamo(2012).International Scientific Productivity on Second-generation Antipsychotic Drugs in Taiwan: A Bibliometric Study.台灣精神醫學,26(2),114-129.
  2. 蔡景宏,陳玉真,郭詩憲,呂宇席(2016)。Prevalence of Antipsychotic Drugs Related to Constipation in Patients with Schizophrenia。臺灣精神醫學，30(4)，294-299。
  3. 林式穀(2016)。Clinical Trials in Psychiatry: Focusing on Antipsychotic Development。臺灣精神醫學，30(2)，91-100+ii。
print cancel